Ellepharm

Ellepharm is a clinical-stage biotechnology company specializing in the development of innovative long-acting injectable (LAI) drug delivery systems. The company leverages its proprietary microsphere and nanocrystal technology platforms to create improved formulations of existing drugs, focusing on therapeutic areas such as metabolic diseases, central nervous system (CNS) disorders, and endocrine conditions. Their lead programs include long-acting versions of GLP-1 receptor agonists and antipsychotics designed to improve patient compliance and therapeutic outcomes. Headquartered in Suzhou, China, Ellepharm aims to address unmet medical needs through advanced formulation science and efficient clinical development.